LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway

BACKGROUND: It is well known that nonalcoholic fatty liver disease (NAFLD) is associated with insulin resistance (IR). LB100, a serine/threonine protein phosphatase 2A (PP2A) inhibitor, is closely related to IR. However, there is little data regarding its direct influence on NAFLD. AIM: To elucidate...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:World J Gastroenterol
Hlavní autoři: Chen, Xue-Yang, Cai, Chang-Zhou, Yu, Meng-Li, Feng, Ze-Min, Zhang, Yu-Wei, Liu, Pei-Hao, Zeng, Hang, Yu, Chao-Hui
Médium: Artigo
Jazyk:Inglês
Vydáno: Baishideng Publishing Group Inc 2019
Témata:
Basic Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906208/
https://ncbi.nlm.nih.gov/pubmed/31832001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v25.i45.6607
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky